J. Pujol

发表

Prediction of survival benefits from progression-free survival in patients with advanced non small cell lung cancer: Evidence from a pooled analysis of 2,838 patients randomized in 7 trials

M. Buyse, V. Georgoulias, F. Fossella, 2008 .

Canakinumab with and without pembrolizumab in patients with resectable non-small-cell lung cancer: CANOPY-N study design.

Edward S. Kim, M. Tsuboi, T. Mok, 2021, Future oncology.

Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)

Jean Mosser, Franck Morin, Gérard Zalcman, 2016, The Lancet.

Final Efficacy and Safety Results of Pemetrexed Continuation Maintenance Therapy in the Elderly from the PARAMOUNT Phase III Study

C. Gridelli, Michael Thomas, F. de Marinis, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Safety and Immunogenicity of the PRAME Cancer Immunotherapeutic in Patients with Resected Non–Small Cell Lung Cancer: A Phase I Dose Escalation Study

T. De Pas, J. Pujol, M. Debois, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Interleukin-1 release by alveolar macrophages in asthmatic patients and healthy subjects.

J. Pujol, P. Godard, J. Clot, 1990, International archives of allergy and applied immunology.

Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC).

J. Pujol, J. Trédaniel, E. Quoix, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Second-line treatment for advanced non-small cell lung cancer: a systematic review.

J. Pujol, F. Barlesi, W. Jacot, 2006, Lung cancer.

Dose-finding, pharmacokinetic and phase II study of docetaxel in combination with gemcitabine in patients with inoperable non-small cell lung cancer.

J. Pujol, C. Ardiet, X. Quantin, 2001, Lung cancer.

Immune response induced in small-cell lung cancer by maintenance therapy with interferon gamma.

J. Jett, J. Pujol, J. Su, 1993, Journal of the National Cancer Institute.

Long term analysis of survival in the European randomized trial comparing vinorelbine/cisplatin to vindesine/cisplatin and vinorelbine alone in advanced non-small cell lung cancer.

J. Soria, J. Pujol, J. Douillard, 2001, The oncologist.

Summary report of the Standards, Options and Recommendations for the management of patients with non-small-cell lung carcinoma (2000)

E. Touboul, T. Molina, E. Lemarié, 2003, British Journal of Cancer.

Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer.

J. von Pawel, A. Ardizzoni, J. Pujol, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A three-arm trial of vinorelbine (Navelbine) plus cisplatin, vindesine plus cisplatin, and single-agent vinorelbine in the treatment of non-small cell lung cancer: an expanded analysis.

J. Pujol, A. Monnier, J. Douillard, 1994, Seminars in oncology.

Phenotypic heterogeneity studied by immunohistochemistry and aneuploidy in non-small cell lung cancers.

J. Bousquet, J. Pujol, P. Godard, 1989, Cancer research.

Neoadjuvant etoposide, ifosfamide, and cisplatin followed by concomitant thoracic radiotherapy and continuous cisplatin infusion in stage IIIb non-small cell lung cancer.

J. Pujol, T. Lafontaine, D. Cupissol, 1999, Chest.

Phase I Study of percutaneous 4-hydroxy-tamoxifen with analyses of 4-hydroxy-tamoxifen concentrations in breast cancer and normal breast tissue

P. Rouanet, J. Fourtillan, J. Pujol, 2004, Cancer Chemotherapy and Pharmacology.

A randomized trial comparing adjuvant chemotherapy with gemcitabine plus cisplatin with docetaxel plus cisplatin in patients with completely resected non-small-cell lung cancer with quality of life as the primary objective.

P. Auquier, J. Pujol, F. Barlesi, 2015, Interactive cardiovascular and thoracic surgery.

Gefitinib (IRESSA) with Vinorelbine or Vinorelbine/Cisplatin for Chemotherapy-Naive Non-small Cell Lung Cancer Patients

J. Pujol, R. Feld, S. Laurie, 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Development and Validation of a Simplified Prognostic Score in SCLC

O. Molinier, J. Daurès, J. Pujol, 2020, JTO clinical and research reports.

Cardiorespiratory fitness in patients with advanced non-small cell lung cancer: why is this feature important to evaluate? Can it be improved?

J. Pujol, X. Quantin, M. Chakra, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

PARAMOUNT: Phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo plus BSC immediately following induction treatment with pem plus cisplatin for advanced nonsquamous non-small cell lung cancer (NSCLC).

C. Gridelli, F. de Marinis, L. Paz-Ares, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

In situ evaluation of growth fraction determined by monoclonal antibody Ki-67 and ploidy in surgically resected non-small cell lung cancers.

J. Pujol, H. Pujol, F. Michel, 1990, Cancer research.

Safety and Immunogenicity of MAGE-A3 Cancer Immunotherapeutic with or without Adjuvant Chemotherapy in Patients with Resected Stage IB to III MAGE-A3-Positive Non–Small-Cell Lung Cancer

G. Fasola, D. Atanackovic, J. Vansteenkiste, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Staging metastasis profile of non-small cell lung cancer: a new paradigm?

J. Pujol, M. Chakra, 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Serum EGF-receptor and HER-2 extracellular domains and prognosis of non-small-cell lung cancer

P. Lamy, J. Pujol, W. Jacot, 2004, British Journal of Cancer.

Phase I-II study of high dose epirubicin plus cisplatin in unresectable non-small-cell lung cancer: searching for the maximal tolerated dose.

J. Daurès, J. Pujol, X. Quantin, 2000, American journal of clinical oncology.

Etoposide plus cisplatin with or without the combination of 4'-epidoxorubicin plus cyclophosphamide in treatment of extensive small-cell lung cancer: a French Federation of Cancer Institutes multicenter phase III randomized study.

E. Lemarié, B. Milleron, J. Daurès, 2001, Journal of the National Cancer Institute.

Preliminary Results of Combined Therapy with Topotecan and Carboplatin in Advanced Non-Small-Cell Lung Cancer

J. von Pawel, J. Pujol, G. Ross, 2001, Oncology.

Phase ii comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer.

M. Ranson, J. von Pawel, U. Gatzemeier, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term results of neoadjuvant ifosfamide, cisplatin, and etoposide combination in locally advanced non-small-cell lung cancer.

J. Pujol, T. le Chevalier, M. Hayot, 1994, Chest.

Induction therapy for NSCLC: a consensus report

R. Mirimanoff, R. Ginsberg, A. Gregor, 1991 .

Standards, Options et Recommandations pour la prise en charge des patients atteints d'un cancer bronchique primitif de stade I ou II traités par irradiation exclusive.

E. Touboul, B. Milleron, J. Lagrange, 2001 .

Detection of lymph node metastases in lung cancer: comparison of 131I-anti-CEA-anti-CA 19-9 immunoscintigraphy versus computed tomography.

M. Ychou, J. Pujol, P. Godard, 1994, Lung cancer.

[Smoking cessation in patients with lung cancer].

J. Pujol, X. Quantin, A. Stoebner-Delbarre, 2007, Revue des maladies respiratoires.

Randomized phase II-III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial†.

P. Lamy, J. Pujol, G. Zalcman, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Circulating Serum Vascular Endothelial Growth Factor is Not a Prognostic Factor of Non-small Cell Lung Cancer

J. Daurès, P. Lamy, J. Pujol, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Detection of known and novel ALK fusion transcripts in lung cancer patients using next-generation sequencing approaches

P. Brousset, J. Mazières, J. Solassol, 2017, Scientific Reports.

Dose-intensity of a four-drug chemotherapy regimen with or without recombinant human granulocyte-macrophage colony-stimulating factor in extensive-stage small-cell lung cancer: a multicenter randomized phase III study.

B. Milleron, D. Spaeth, J. Pujol, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of alternating combination chemotherapy in small cell lung cancer

P. Demoly, G. Romieu, J. Pujol, 1991 .

Should chemotherapy (Cx) for advanced non-small cell lung cancer (NSCLC) be platinum-based? A literature-based meta-analysis of randomized trials

J. Daurès, J. Pujol, F. Barlesi, 2005 .

Biologic staging of non-small-cell lung cancer: prospect or proposal?

J. Pujol, F. Barlesi, W. Jacot, 2005, Clinical lung cancer.

Immunohistochemical detection of p53 protein and prognosis of surgically resected non-small-cell lung cancer.

J. Pujol, I. Serre, X. Quantin, 1997, Cancer detection and prevention.

Hypodiploidy, Ki-67 growth fraction and prognosis of surgically resected lung cancers.

P. Demoly, J. Pujol, D. Jaffuel, 1996, British Journal of Cancer.

Neural cell adhesion molecule and prognosis of surgically resected lung cancer.

P. Demoly, J. Laurent, J. Daurès, 1993, The American review of respiratory disease.

Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours

M. Ychou, J. Pujol, W. Jacot, 2004, The British journal of dermatology.

CYFRA 21-1 is a prognostic determinant in non-small-cell lung cancer: results of a meta-analysis in 2063 patients

M Paesmans, O. Molinier, M. Paesmans, 2004, British Journal of Cancer.

Reply to Dr J Watine

O. Molinier, J. Pujol, J. Grenier, 2001 .

Cytokeratins as serum markers in lung cancer: a comparison of CYFRA 21-1 and TPS.

J. Pujol, T. Lafontaine, É. Parrat, 1996, American journal of respiratory and critical care medicine.

Pro-gastrin-releasing peptide, neuron specific enolase and chromogranin A as serum markers of small cell lung cancer.

P. Lamy, J. Pujol, A. Kramar, 2000, Lung cancer.

Patient participation in thoracic cancer clinical trials.

B. Milleron, J. Pujol, M. Chakra, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Circulating Tumor DNA as a Prognostic Determinant in Small Cell Lung Cancer Patients Receiving Atezolizumab

O. Molinier, J. Pujol, M. Denis, 2020, Journal of clinical medicine.

[Medical treatment of small cell lung cancer: Can we leave the area of cisplatin-etoposide?]

J. Pujol, C. Gozé, B. Roch, 2018, Bulletin du cancer.

Combination of chemotherapy without platinum compounds in the treatment of advanced non-small cell lung cancer: a systematic review of phase III trials.

J. Pujol, F. Barlesi, 2005, Lung cancer.

Phase II pilot study of Ifosfamide-Cisplatine-Etoposide association as Neo-Adjuvant chemotherapy in locally advanced non-small cell lung cancers

J. Rossi, R. Arriagada, J. Daurès, 1991 .

Skin test reactivity in patients suffering from lung and breast cancer.

J. Bousquet, J. Pujol, P. Godard, 1991, The Journal of allergy and clinical immunology.

Predictive factors of tumor response and prognostic factors of survival during lung cancer chemotherapy.

J. Pujol, J. Grenier, X. Quantin, 1998, Cancer detection and prevention.

r-metHuG-CSF support to ifosfamide, cisplatin, etoposide chemotherapy in non-small cell lung cancer.

J. Pujol, F. Michel, V. Gautier, 1996, Lung cancer.

Neoadjuvant chemotherapy of locally advanced non-small cell lung cancer.

R. Arriagada, J. Pujol, T. Chevalier, 1995, Lung cancer.

Clinical evaluation of serum tissue polypeptide-specific antigen (TPS) in non-small cell lung cancer.

J. Pujol, P. Godard, E. Cooper, 1994, European journal of cancer.

Clinical evaluation of serum tumour marker CA 242 in non-small cell lung cancer.

J. Pujol, P. Godard, E. Cooper, 1993, British Journal of Cancer.

Role of the YAP-1 Transcriptional Target cIAP2 in the Differential Susceptibility to Chemotherapy of Non-Small-Cell Lung Cancer (NSCLC) Patients with Tumor RASSF1A Gene Methylation from the Phase 3 IFCT-0002 Trial

J. Pujol, G. Zalcman, E. Bergot, 2019, Cancers.

Lung cancer: an emerging epidemic in the human immunodeficiency virus-infected population.

J. Pujol, V. Le Moing, J. Reynes, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Pilot study of neoadjuvant ifosfamide, cisplatin, and etoposide in locally advanced non-small cell lung cancer.

J. Rossi, R. Arriagada, J. Daurès, 1990, European journal of cancer.

Combined treatment modalities in non-small cell lung cancer: a French experience

R. Arriagada, B. Dautzenberg, J. Pujol, 1993 .

MACVIA-LR, Reference site of the European Innovation Partnership on Active and Healthy Ageing (EIP on AHA) in Languedoc Roussillon

J. Robine, B. Bardy, P. Courtet, 2014 .

Platelet function: aggregation by PAF or sequestration in lung is not modified during immediate or late allergen-induced bronchospasm in man.

J. Pujol, J. Cazenave, G. Pauli, 1989, The Journal of allergy and clinical immunology.

Identification of an alveolar macrophage-derived activity in bronchial asthma that enhances leukotriene C4 generation by human eosinophils stimulated by ionophore A23187 as a granulocyte-macrophage colony-stimulating factor.

J. Pujol, T. Lee, P. Godard, 1989, The American review of respiratory disease.

Cell proliferation in the bronchial mucosa of asthmatics and chronic bronchitics.

J. Bousquet, P. Demoly, P. Chanez, 1994, American journal of respiratory and critical care medicine.

PLS. plenary session

C. Obasaju, C. Gridelli, L. Sequist, 2012 .

Phase I I C omparator S tudy o f O ral V ersus I ntravenous Topotecan i n P atients W ith C hemosensitive S mall-Cell Lung C ancer

M. Ranson, U. Gatzemeier, J. Pujol, 2011 .

Fos immunoreactivity assessment on human normal and pathological bronchial biopsies.

J. Bousquet, P. Demoly, P. Chanez, 1995, Respiratory medicine.

Is Darbepoietin Alfa Linked to Mortality During Non-Small Cell Lung Cancer Chemotherapy?

J. Pujol, B. Roch, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Substance P activation of bronchoalveolar macrophages from asthmatic patients and normal subjects

J. Bousquet, P. Chanez, J. Pujol, 1989, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

Immunohistochemical study of P-glycoprotein distribution in lung cancer.

J. Pujol, C. Marty-ané, H. Pujol, 1993, Lung cancer.

Interstitial pulmonary disease induced by occupational exposure to paraffin.

J. Bousquet, J. Pujol, P. Godard, 1990, Chest.

Long-Term and Low-Grade Safety Results of a Phase III Study (PARAMOUNT): Maintenance Pemetrexed Plus Best Supportive Care Versus Placebo Plus Best Supportive Care Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non e Small-Cell Lung Cancer

C. Gridelli, L. Paz-Ares, J. Pujol, 2014 .

Bacterial ribosomal immunostimulants prime alveolar macrophages in vivo to produce interleukin 1 in vitro.

B. Klein, J. Pujol, P. Godard, 1991, Chest.

MAGE-A3 cancer immunotherapeutic in resected stage IB-III NSCLC patients with or without sequential or concurrent chemotherapy.

G. Fasola, D. Atanackovic, J. Vansteenkiste, 2012 .

Preservation with a retrograde second flushing of Eurocollins in clinical lung transplantation.

J. Pujol, A. Álvarez, F. Cerezo, 1999, Transplantation proceedings.

A new simplified comorbidity score as a prognostic factor in non-small-cell lung cancer patients: description and comparison with the Charlson's index

J. Daurès, J. Pujol, W. Jacot, 2005, British Journal of Cancer.

92 CPT 11 (Irinotecan) in pretreated small cell lung cancer (SCLC): A phase II study in patients progressing after a first response (preliminary results)

J. Pujol, J. Douillard, T. Chevalier, 1995 .

Lung Cancer in France.

P. Giraud, J. Pujol, M. Denis, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Concomitant brain radiotherapy and vinorelbine-ifosfamide-cisplatin chemotherapy in brain metastases of non-small cell lung cancer.

J. Pujol, X. Quantin, F. Michel, 1999, Lung cancer.

Multimodality Treatment Program in Invasive Thymic Epithelial Tumor

J. Pujol, W. Jacot, S. Valette, 2005, American journal of clinical oncology.

Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients.

P Chomy, J L Pujol, J. Pujol, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combination chemotherapy without cisplatin in the treatment of advanced non-small cell lung cancer.

J. Pujol, W. Jacot, X. Quantin, 2002, Lung cancer.

Post-Traumatic Stress Disorder and Health-Related Quality of Life in Patients and Their Significant Others Facing Lung Cancer Diagnosis: Intrusive Thoughts as Key Factors

J. Daurès, J. Pujol, C. Plassot, 2013 .

Increasing Transparency in Author Contributions to Manuscripts: Enhanced Policy on Ghost and Honorary Authorships.

A. Bezjak, S. Mandrekar, D. Camidge, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

An individual patient-data meta-analysis of metronomic oral vinorelbine in metastatic non-small cell lung cancer

M. Mencoboni, G. Banna, J. Daurès, 2019, PloS one.

[Anti-Hu antibodies: a remarkable immulogical phenotype for several paraneoplastic syndromes].

J. Pujol, B. Carlander, J. Di Mercurio, 2013, Revue des maladies respiratoires.

Spontaneous complete remission of a non-small cell lung cancer associated with anti-Hu antibody syndrome.

J. Pujol, W. Jacot, P. Labauge, 2007, Journal of Thoracic Oncology.

Unexplained CD4‐positive T‐cell deficiency in non‐HIV patients presenting as a Pneumocystis carinii pneumonia

P. Chanez, J. Pujol, P. Godard, 1991, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer.

J. Daurès, J. Pujol, A. Daver, 1993, Cancer research.

Abemaciclib in Combination With Pembrolizumab for Stage IV KRAS-Mutant or Squamous NSCLC: A Phase 1b Study

P. Jänne, J. Mazières, J. Vansteenkiste, 2021, JTO clinical and research reports.

Detection of known and novel ALK fusion transcripts in lung cancer patients using next-generation sequencing approaches

P. Brousset, J. Mazières, J. Solassol, 2017, Scientific Reports.

Inhibition of DDR1 enhances in vivo chemosensitivity in KRAS-mutant lung adenocarcinoma.

Miguel A. Mosteiro, P. Jänne, M. Barbacid, 2020, JCI insight.

Clinical Relevance of Autoantibody Detection in Lung Cancer

J. Solassol, A. Mangé, T. Maudelonde, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Aneuploidy and prognosis of non-small-cell lung cancer: a meta-analysis of published data

J L Pujol, J. Daurès, J. Pujol, 2001, British Journal of Cancer.

Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial.

Moon Soo Kim, N. Altorki, P. Therasse, 2016, The Lancet. Oncology.

Cachexia - sarcopenia as a determinant of disease control rate and survival in non-small lung cancer patients receiving immune-checkpoint inhibitors.

J. Daurès, J. Pujol, S. Bommart, 2020, Lung cancer.

A Randomized Non‐Comparative Phase II Study of Anti‐Programmed Cell Death‐Ligand 1 Atezolizumab or Chemotherapy as Second‐Line Therapy in Patients With Small Cell Lung Cancer: Results From the IFCT‐1603 Trial

O. Molinier, J. Pujol, M. Denis, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

MSH2/BRCA1 expression as a DNA-repair signature predicting survival in early–stage lung cancer patients from the IFCT-0002 Phase 3 Trial

F. Galateau-Sallé, E. Brambilla, O. Molinier, 2016, Oncotarget.

High TUBB3 Expression, an Independent Prognostic Marker in Patients with Early Non–Small Cell Lung Cancer Treated by Preoperative Chemotherapy, Is Regulated by K-Ras Signaling Pathway

E. Brambilla, J. Camonis, J. Pujol, 2012, Molecular Cancer Therapeutics.

Molecular Medicine in Practice High TUBB 3 Expression , an Independent Prognostic Marker in Patients with Early Non – Small Cell Lung Cancer Treated by Preoperative Chemotherapy , Is Regulated by KRas Signaling Pathway

E. Brambilla, J. Camonis, J. Pujol, 2012 .

Neuroendocrine and cytokeratin serum markers as prognostic determinants of small cell lung cancer.

P. Lamy, J. Pujol, W. Jacot, 2003, Lung cancer.

Tumor-tissue and plasma concentrations of platinum during chemotherapy of non-small-cell lung cancer patients

J. Pujol, D. Cupissol, F. Michel, 2004, Cancer Chemotherapy and Pharmacology.

Phase II study of nitrosourea fotemustine as single-drug chemotherapy in poor-prognosis non-small-cell lung cancer.

J. Pujol, A. Monnier, J. Douillard, 1994, British Journal of Cancer.

Chest tumor response during lung cancer chemotherapy. Computed tomography vs fiberoptic bronchoscopy.

J. Pujol, P. Godard, É. Parrat, 1993, Chest.

Weekly Paclitaxel Combined with Monthly Carboplatin in Elderly Patients with Advanced Non-small Cell Lung Cancer: A Multicenter Phase II Study

B. Milleron, O. Molinier, J. Pujol, 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.

C. Gridelli, Michael Thomas, F. de Marinis, 2012, The Lancet. Oncology.

Ultra-sensitive EGFRT790M Detection as an Independent Prognostic Marker for Lung Cancer Patients Harboring EGFRdel19 Mutations and Treated with First-generation TKIs

P. Brousset, J. Mazières, J. Solassol, 2019, Clinical Cancer Research.

Third CECOG consensus on the systemic treatment of non-small-cell lung cancer.

C. Gridelli, F. Hirsch, V. Georgoulias, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Consensus on medical treatment of non-small cell lung cancer.

Christina J. Herold, C. Gridelli, F. Hirsch, 2002, Lung cancer.

Human Immunodeficiency Virus Infection and Non-small Cell Lung Cancer: Survival and Toxicity of Antineoplastic Chemotherapy in a Cohort Study

L. Cuzin, J. Pujol, S. Eymard-Duvernay, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Interactions between cytotoxic chemotherapy and antiretroviral treatment in human immunodeficiency virus-infected patients with lung cancer.

J. Pujol, V. Le Moing, J. Reynes, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Imaging of postoperative complications following surgery for lung cancer.

J. Pujol, C. Marty-ané, S. Bommart, 2017, Diagnostic and interventional imaging.

PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.

C. Gridelli, Michael Thomas, F. de Marinis, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent

J. Daurès, J. Pujol, Carestia, 2000, British Journal of Cancer.

Cyfra 21-1, a new marker of lung cancer.

J. Daurès, J. Pujol, J. Grenier, 1994, Nuclear medicine and biology.

Lung Cancer Screening with Chest Computed Tomography in People Living with HIV: A Review by the Multidisciplinary CANCERVIH Working Group

B. Milleron, J. Pujol, J. Spano, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A randomised trial comparing preoperative to perioperative chemotherapy in early-stage non-small-cell lung cancer (IFCT 0002 trial).

E. Lemarié, B. Milleron, O. Molinier, 2013, European journal of cancer.

Is Weight Loss a Loss of Chance in Patients Receiving Chemoradiotherapy?

J. Pujol, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer.

J. Soria, L. Amler, E. Juhász, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase II-III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: Results from the IFCT-0802 trial.

J. Pujol, G. Zalcman, D. Moro-Sibilot, 2014 .

Survival of patients with resected N2 non-small-cell lung cancer: evidence for a subclassification and implications.

J. Pignon, F. André, A. Dujon, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Patterns of relapse of N2 nonsmall‐cell lung carcinoma patients treated with preoperative chemotherapy

F. André, A. Dujon, J. Pujol, 2001, Cancer.

Consolidation nivolumab and ipilimumab versus observation in limited-disease small cell lung cancer after chemo-radiotherapy - Results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial.

K. Nackaerts, U. Dafni, D. de Ruysscher, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Concomitant brain radiotherapy and high-dose ifosfamide in brain relapses of lung cancer.

J. Pujol, P. Godard, X. Quantin, 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

Interleukin-1 alpha and soluble interleukin-2 receptor during small cell lung cancer chemotherapy: comparison of high chemotherapy dose with rhGM-CSF and standard chemotherapy dose without rhGM-CSF.

J. Pujol, F. Michel, V. Gautier, 1995, Lung cancer.

Cyfra 21-1, neuron specific enolase and prognosis of non-small cell lung cancer: prospective study in 621 patients.

J L Pujol, J. Pujol, J. Boher, 2001, Lung cancer.

Lung cancer chemotherapy. Response-survival relationship depends on the method of chest tumor response evaluation.

J. Daurès, J. Pujol, P. Godard, 1996, American journal of respiratory and critical care medicine.

Serum Proteomic Profiling of Lung Cancer in High-Risk Groups and Determination of Clinical Outcomes

J. Daurès, J. Solassol, A. Mangé, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase II study of docetaxel in the treatment of patients with advanced non-small cell lung cancer in routine daily practice.

R. Stupp, J. Pujol, J. Douillard, 2000, Lung cancer.

Quality of life and comorbidity score as prognostic determinants in non-small-cell lung cancer patients.

J. Daurès, J. Pujol, W. Jacot, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Serum HE4: An Independent Prognostic Factor in Non-Small Cell Lung Cancer

P. Lamy, J. Pujol, C. Plassot, 2015, PloS one.

Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin.

E. Lemarié, B. Milleron, D. Spaeth, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Notch inhibition overcomes resistance to Tyrosine Kinase Inhibitors in EGFR-driven lung adenocarcinoma.

Kwok-Kin Wong, J. Colinge, Y. Yarden, 2019, The Journal of clinical investigation.

Switch maintenance chemotherapy versus observation after carboplatin and weekly paclitaxel doublet chemotherapy in elderly patients with advanced non-small cell lung cancer: IFCT-1201 MODEL trial.

O. Molinier, J. Pujol, P. Dumont, 2020, European journal of cancer.

Safety, Resource Use, and Quality of Life in Paramount: A Phase III Study of Maintenance Pemetrexed Versus Placebo after Induction Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer

C. Gridelli, F. de Marinis, R. Ramlau, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Structure of general thoracic surgery in Europe.

P. V. Van Schil, P. Zannini, F. Venuta, 2001, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes.

M. Aristides, G. Scagliotti, C. Gridelli, 2005, Lung cancer.

Comparison of Docetaxel- and Vinca Alkaloid–Based Chemotherapy in the First-line Treatment of Advanced Non-small Cell Lung Cancer: A Meta-analysis of Seven Randomized Clinical Trials

V. Georgoulias, F. Fossella, S. Laporte, 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase III double-blind, placebo-controlled study of thalidomide in extensive-disease small-cell lung cancer after response to chemotherapy: an intergroup study FNCLCC cleo04 IFCT 00-01.

J. Pujol, M. Tanguy, E. Quoix, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Epirubicin and ifosfamide in relapsed or refractory small cell lung cancer patients.

O. Molinier, J. Pujol, W. Jacot, 2012, Lung cancer.

Chest tumor response measurement during lung cancer chemotherapy. Comparison between computed tomography and standard roentgenography.

P. Demoly, J. Daurès, J. Pujol, 1992, The American review of respiratory disease.

Efficacy and safety of maintenance pemetrexed in patients with advanced nonsquamous non-small cell lung cancer following pemetrexed plus cisplatin induction treatment: A cross-trial comparison of two phase III trials.

G. Scagliotti, C. Gridelli, F. de Marinis, 2014, Lung cancer.

Qualitative study of patients’ decision-making when accepting second-line treatment after failure of first-line chemotherapy

J. Pujol, B. Roch, J-P Mérel, 2018, PloS one.

LBA84 Consolidation ipilimumab and nivolumab vs observation in limited stage SCLC after chemo-radiotherapy: Results from the ETOP/IFCT 4-12 STIMULI trial

K. Nackaerts, U. Dafni, D. Ruysscher, 2020 .

Time to diagnosis of lung cancer: technical and pyschological factors that slow down diagnostic and treatment timelines.

J. Pujol, X. Quantin, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Should chemotherapy combinations for advanced non-small cell lung cancer be platinum-based? A meta-analysis of phase III randomized trials.

J. Daurès, J. Pujol, F. Barlesi, 2006, Lung cancer.

Brain metastases at the time of presentation of non-small cell lung cancer: a multi-centric AERIO analysis of prognostic factors

F. André, J. Pujol, T. Chevalier, 2001, British Journal of Cancer.

A prospective randomized phase III, double-blind, placebo-controlled study of thalidomide in extended-disease (ED) SCLC patients after response to chemotherapy (CT): An intergroup study FNCLCC Cleo04 - IFCT 00-01.

J. Pujol, M. Tanguy, E. Quoix, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials

M. Buyse, J. Pignon, V. Georgoulias, 2013, BMJ Open.

C. Gridelli, F. de Marinis, L. Paz-Ares, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cetuximab plus platinum-based chemotherapy as 1st-line treatment in patients with non-small cell lung cancer (NSCLC): a meta-analysis of randomized phase II/III trials

T. Lynch, F. Shepherd, R. Pirker, 2009 .

Meta-analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small cell lung cancer.

K. O'Byrne, T. Lynch, F. Shepherd, 2014, Lung cancer.

Survival without Common Toxicity Criteria Grade 3/4 Toxicity for Pemetrexed Compared with Docetaxel in Previously Treated Patients with Advanced Non-small Cell Lung Cancer (NSCLC): A Risk-Benefit Analysis

D. Berry, M. Salzberg, J. Pujol, 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Comparison of an expert system with other clinical scores for the evaluation of severity of asthma.

J L Pujol, J Bousquet, P Godard, 1996, The European respiratory journal.

Successful docetaxel tolerance induction

P. Demoly, J. Pujol, D. Messaad, 2003, Allergy.

[Standards, Options and Recommendations for the management of non-small cell lung carcinoma patients].

E. Touboul, T. Molina, E. Lemarié, 2003, Bulletin du cancer.

CHEMOTHERAPY (CT) PLUS CETUXIMAB AS 1ST-LINE TREATMENT FOR ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): META-ANALYSIS OF INDIVIDUAL PATIENT DATA

T. Lynch, F. Shepherd, R. Pirker, 2010 .

Recursive Partitioning Analysis Groups II–III Brain Metastases of Non-small Cell Lung Cancer: A Phase II Randomized Study Comparing Two Concurrent Chemoradiotherapy Regimens

J. Pujol, M. Bozonnat, X. Quantin, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[Standards, options and recommendations for the management of locally advanced non small cell lung carcinoma].

E. Touboul, E. Lemarié, B. Milleron, 2001, Bulletin du cancer.

Evaluation of changes in renal function in PARAMOUNT: a phase III study of maintenance pemetrexed plus best supportive care versus placebo plus best supportive care after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer

C. Gridelli, F. de Marinis, R. Ramlau, 2018, Current medical research and opinion.

[Oncogenes and anti-oncogenes in lung cancer].

P. Demoly, J. Pujol, P. Godard, 1994, Presse medicale.

[Regression of hippocratic fingers during chemotherapy of bronchial cancer].

J. Pujol, P. Godard, É. Parrat, 1991, Revue de pneumologie clinique.

How Preconceptions About Lung Cancer Treatment Interact With Medical Discourse for Patients Who Accept Chemotherapy?

J. Pujol, J-P Mérel, Caroline J Roth, 2017, Psycho-oncology.

Long-term and low-grade safety results of a phase III study (PARAMOUNT): maintenance pemetrexed plus best supportive care versus placebo plus best supportive care immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.

C. Gridelli, Michael Thomas, F. de Marinis, 2014, Clinical lung cancer.

Randomised, multicentre phase II study assessing two doses of docetaxel (75 or 100 mg/m2) as second-line monotherapy for non-small-cell lung cancer.

E. Lemarié, B. Milleron, J. Pujol, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

IFCT0002 phase III study comparing a preoperative (PRE) and a perioperative (PERI) chemotherapy with two different CT regimens in resectable non-small cell lung cancer (NSCLC): Early results

B. Milleron, J. Pujol, E. Quoix, 2007 .

Results of the IFCT 0002 phase III study comparing a preoperative and a perioperative chemotherapy (CT) with two different CT regimens in resectable non-small cell lung cancer (NSCLC).

B. Milleron, J. Pujol, E. Quoix, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Markov model and markers of small cell lung cancer: assessing the influence of reversible serum NSE, CYFRA 21-1 and TPS levels on prognosis

J. Daurès, J. Pujol, J. Boher, 1999, British Journal of Cancer.

Perception of Lung Cancer among the General Population and Comparison with Other Cancers

B. Milleron, J. Mazières, J. Pujol, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Randomized phase II study of gemcitabine-oxaliplatin or gemcitabine-cisplatin in chemonaive patients with advanced non-small cell lung cancer (NSCLC)-CLEO 05.

J. Pujol, T. le Chevalier, X. Sun, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparison of docetaxel and vinca alkaloid, alone or in combination with other chemotherapy agents, in the first-line treatment of advanced non-small cell lung cancer (NSCLC): A meta-analysis.

V. Georgoulias, S. Laporte, J. Pujol, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

C. Gridelli, F. de Marinis, R. Ramlau, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Typical and atypical bronchopulmonary carcinoid tumors: a clinicopathologic and KI-67-labeling study.

M. Picot, V. Costes, J. Pujol, 1995, Human pathology.

A randomized non-comparative phase II study of anti-PD-L1 ATEZOLIZUMAB or chemotherapy as second-line therapy in patients with small cell lung cancer: Results from the IFCT-1603 trial.

L. Thiberville, O. Molinier, J. Mazières, 2018, Annals of Oncology.

C. Gridelli, Michael Thomas, F. de Marinis, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Epirubicin and ifosfamide in relapsed or refractory small cell lung cancer patients.

O. Molinier, J. Pujol, W. Jacot, 2012, Lung cancer.

[The reference site of the European Innovation Partnership on Active and Healthy Aging MACVIA-LR (the fight against chronic diseases for an active and healthy aging in Languedoc-Roussillon)].

P. Claret, J. Robine, B. Bardy, 2015, Presse medicale.

[Medical treatment of small cell lung cancer: Can we leave the area of cisplatin-etoposide?]

J. Pujol, C. Gozé, B. Roch, 2018, Bulletin du cancer.

Circulating Serum Vascular Endothelial Growth Factor is Not a Prognostic Factor of Non-small Cell Lung Cancer

J. Daurès, P. Lamy, J. Pujol, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Brief Report: A Multidisciplinary Initial Workup for Suspected Lung Cancer as Fast-Track Intervention to Histopathologic Diagnosis

J. Pujol, S. Bommart, I. Serre, 2023, JTO clinical and research reports.

Non-small cell lung cancer, early stage

L. Bubendorf, T. Yamanaka, M. Okada, 2012 .

Recursive Partitioning Analysis Groups II–III Brain Metastases of Non-small Cell Lung Cancer: A Phase II Randomized Study Comparing Two Concurrent Chemoradiotherapy Regimens

J. Pujol, M. Bozonnat, X. Quantin, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.